[go: up one dir, main page]

AR064077A1 - Composiciones bajo forma de unguento sin vaselina que comprende un derivado de vitamina d y eventualmente un anti-inflamatorio esteroide - Google Patents

Composiciones bajo forma de unguento sin vaselina que comprende un derivado de vitamina d y eventualmente un anti-inflamatorio esteroide

Info

Publication number
AR064077A1
AR064077A1 ARP070105356A ARP070105356A AR064077A1 AR 064077 A1 AR064077 A1 AR 064077A1 AR P070105356 A ARP070105356 A AR P070105356A AR P070105356 A ARP070105356 A AR P070105356A AR 064077 A1 AR064077 A1 AR 064077A1
Authority
AR
Argentina
Prior art keywords
vitamin
eventually
derivative
vaseline
inflammatory
Prior art date
Application number
ARP070105356A
Other languages
English (en)
Inventor
Nathalie Willcox
Original Assignee
Galderma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Sa filed Critical Galderma Sa
Publication of AR064077A1 publication Critical patent/AR064077A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Composicion en forma de ungüento, sin vaselina, principalmente para una aplicacion topica, que comprende un derivado de vitamina D y, eventualmente, un agente activo de la familia de los antiinflamatorios esteroides. Uso. Procedimiento.
ARP070105356A 2006-11-30 2007-11-30 Composiciones bajo forma de unguento sin vaselina que comprende un derivado de vitamina d y eventualmente un anti-inflamatorio esteroide AR064077A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0655205A FR2909284B1 (fr) 2006-11-30 2006-11-30 Nouvelles compositions sous forme d'onguent sans vaseline comprenant un derive de vitamine d et eventuellement un anti-inflammatoire steroidien

Publications (1)

Publication Number Publication Date
AR064077A1 true AR064077A1 (es) 2009-03-11

Family

ID=38441906

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070105356A AR064077A1 (es) 2006-11-30 2007-11-30 Composiciones bajo forma de unguento sin vaselina que comprende un derivado de vitamina d y eventualmente un anti-inflamatorio esteroide

Country Status (13)

Country Link
US (4) US8741878B2 (es)
EP (1) EP2101726A2 (es)
JP (1) JP2011504870A (es)
KR (1) KR20090084898A (es)
CN (1) CN101541304B (es)
AR (1) AR064077A1 (es)
AU (1) AU2007327368B2 (es)
BR (1) BRPI0717695A2 (es)
CA (1) CA2670601A1 (es)
FR (1) FR2909284B1 (es)
MX (1) MX2009005307A (es)
RU (1) RU2448713C2 (es)
WO (1) WO2008065316A2 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2931662B1 (fr) * 2008-05-30 2010-07-30 Galderma Res & Dev Nouvelles compositions depigmentantes sous forme d'une composition anhydre sans vaseline et sans elastomere comprenant un derive phenolique solubilise.
FR2931663B1 (fr) * 2008-05-30 2010-07-30 Galderma Res & Dev Nouvelles compositions depigmentantes anhydre comprenant un derive phenolique solubilise.
JP2012513387A (ja) * 2008-12-23 2012-06-14 ガルデルマ・ソシエテ・アノニム 感水性の活性成分を含む、局所用医薬組成物
US8557264B2 (en) 2009-12-10 2013-10-15 3rd Rock Sunblock, Inc. Glycerine based jelly compositions
US9254296B2 (en) 2009-12-22 2016-02-09 Leo Pharma A/S Pharmaceutical composition comprising vitamin D analogue and cosolvent-surfactant mixture
AU2009357263B2 (en) * 2009-12-22 2015-04-09 Leo Pharma A/S Pharmaceutical composition comprising vitamin D analogue and cosolvent-surfactant mixture
US20130023501A1 (en) * 2009-12-22 2013-01-24 Leo Pharma A/S Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue
US20120322776A1 (en) * 2009-12-22 2012-12-20 Leo Pharma A/S Cutaneous composition comprising vitamin d analogue and a mixture of solvent and surfactants
JP2014508796A (ja) * 2011-03-24 2014-04-10 レオ ファーマ アクティーゼルスカブ 脂質ナノ粒子とコルチコステロイドまたはビタミンｄ誘導体とを含む組成物
RU2496476C1 (ru) * 2012-08-10 2013-10-27 Федеральное государственное бюджетное учреждение "Уральский научно-исследовательский институт дерматовенерологии и иммунопатологии" Министерства здравоохранения и социального развития Российской Федерации (ФГБУ "УрНИИДВиИ" Минздравсоцразвития России) Средство наружной терапии для больных атопическим дерматитом
CN103142495B (zh) * 2013-03-21 2014-08-20 青岛正大海尔制药有限公司 骨化三醇混悬颗粒及其制备方法
CN103142467B (zh) * 2013-03-21 2014-07-02 青岛正大海尔制药有限公司 骨化三醇软膏及其制备方法
CN103142486B (zh) * 2013-03-21 2014-08-20 青岛正大海尔制药有限公司 骨化三醇散剂及其制备方法
US20160235757A1 (en) * 2013-10-11 2016-08-18 Betta Pharmaceuticals Co., Ltd. Icotinib-containing topical skin pharmaceutical compositions and uses thereof
US9913787B2 (en) 2015-05-18 2018-03-13 Guerry L. Grune Glycerine based jelly compositions
CN107157920B (zh) * 2016-03-08 2019-12-27 上海通用药业股份有限公司 一种包含维生素d或其衍生物的半固体制剂的制备方法
CN107157919B (zh) * 2016-03-08 2019-12-27 上海通用药业股份有限公司 一种用于治疗银屑病的半固体制剂的制备方法
CN107157918B (zh) * 2016-03-08 2019-12-27 上海通用药业股份有限公司 一种用于银屑病治疗的半固体制剂的制备方法
CN107157917B (zh) * 2016-03-08 2019-12-27 上海通用药业股份有限公司 一种用于治疗银屑病的软膏的制备方法
CN108969527B (zh) * 2017-05-31 2021-05-11 上海通用药业股份有限公司 一种药物制剂及其制备方法和用途
CN109453180A (zh) * 2018-11-15 2019-03-12 广州南峰生物科技有限公司 生物活性维生素d衍生物或类似物的新用途
CN109568279B (zh) * 2018-12-28 2020-10-20 正大制药（青岛）有限公司 一种氟骨化醇片剂及其制备方法
WO2021162796A1 (en) * 2020-02-11 2021-08-19 Taro Pharmaceutical Industries Ltd. Compositions comprising desoximetasone and tazarotene
CN111743906A (zh) * 2020-04-01 2020-10-09 南通华山药业有限公司 一种阿法骨化醇在制备干预皮肤光损伤外用制剂中的应用
CN114159567B (zh) * 2020-09-10 2023-03-31 南京海融医药科技股份有限公司 一种治疗皮肤病的混悬凝胶剂
CN116531315B (zh) * 2023-03-22 2024-02-13 江苏知原药业股份有限公司 一种卡泊三醇软膏及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6399014A (ja) * 1986-10-15 1988-04-30 Teijin Ltd 乾癬治療用油脂性軟膏剤
FR2719220A1 (fr) * 1994-04-29 1995-11-03 Lafon Labor Nouvelle forme galénique pour l'administration transdermique.
WO1999029325A1 (en) * 1997-12-09 1999-06-17 Chugai Seiyaku Kabushiki Kaisha Lotions containing vitamin d3 derivatives
SK287653B6 (sk) * 1999-04-23 2011-05-06 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Nevodná farmaceutická kompozícia na dermálne použitie
PL212660B1 (pl) * 2000-10-27 2012-11-30 Leo Pharma As Zasadniczo niewodna zelowa kompozycja farmaceutyczna do podawania na skóre oraz jej zastosowanie
FR2848454B1 (fr) * 2002-12-17 2007-03-30 Galderma Res & Dev Composition pharmaceutique comprenant une association de calcitriol et d'un corticosteroide
RU2361594C2 (ru) * 2002-12-17 2009-07-20 Галдерма Са Фармацевтические композиции, включающие комбинацию кальцитриола и клобетазола пропионат
FR2867682B1 (fr) * 2004-03-22 2009-06-05 Galderma Res & Dev Composition pharmaceutique anhydre associant un agent silicone et un principe actif solubilise.
FR2871694B1 (fr) * 2004-06-17 2008-07-04 Galderma Sa Composition pharmaceutique comprenant un onguent oleagineux et deux principes actifs solubilises
KR20080016612A (ko) * 2005-06-10 2008-02-21 갈데르마 소시에떼아노님 약물, 필름형성 실리콘 및 하나 이상의 휘발성 용매를포함하는 국소조성물을 기초로 하는 피부를 통한 약물의조절된 방출

Also Published As

Publication number Publication date
JP2011504870A (ja) 2011-02-17
US8741879B2 (en) 2014-06-03
KR20090084898A (ko) 2009-08-05
RU2009124913A (ru) 2011-01-10
FR2909284A1 (fr) 2008-06-06
AU2007327368A1 (en) 2008-06-05
US20140243297A1 (en) 2014-08-28
RU2448713C2 (ru) 2012-04-27
FR2909284B1 (fr) 2012-09-21
AU2007327368B2 (en) 2013-08-15
WO2008065316A3 (fr) 2008-11-06
MX2009005307A (es) 2009-05-28
CA2670601A1 (fr) 2008-06-05
EP2101726A2 (fr) 2009-09-23
CN101541304B (zh) 2013-05-01
BRPI0717695A2 (pt) 2015-10-27
WO2008065316A2 (fr) 2008-06-05
US20090298801A1 (en) 2009-12-03
CN101541304A (zh) 2009-09-23
US8741878B2 (en) 2014-06-03
US20140256689A1 (en) 2014-09-11
US20130012484A1 (en) 2013-01-10

Similar Documents

Publication Publication Date Title
AR064077A1 (es) Composiciones bajo forma de unguento sin vaselina que comprende un derivado de vitamina d y eventualmente un anti-inflamatorio esteroide
CL2011000214A1 (es) Composicion farmaceutica que comprende progesterona micronizada y aceite de cartamo tipo ii; y uso para el tratamiento de una condicion relacionada con la insuficiencia de secrecion de progesterona.
AR059844A1 (es) Nuevas composiciones topicas en forma de emulsion ac/ag que comprenden un glicol propenetrante
AR048878A1 (es) Composiciones topicas de metadona y metodos para usarlas
AR059843A1 (es) Nuevas composiciones topicas en forma de emulsion ac/ag que comprenden un glicol propenetrante
MX2009010289A (es) Composiciones para administracion nasal.
ECSP088889A (es) Forma nueva de administración de racecadotril
MX2009004203A (es) Combinaciones de paracetamol/ibuprofeno y metodo para su uso.
MX2014008284A (es) Formulacion de liberacion retardada para reducir la frecuencia de orinar y metodos de uso de esta.
CL2011002595A1 (es) Uso de una combinacion de un agente anticancerigeno y un antioxidante para tratar el cancer; y compicicion farmaceutica que comprende dicha combinacion.
CL2008000510A1 (es) Compuestos conjugados farmaco-ligandos, que se unen a citotoxinas potentes; composicion farmaceutica; y uso para retardar o detener el crecimiento de un tumor en un mamifero.
CL2008000442A1 (es) Composicion farmaceutica que comprende a un quitosano, un ingrediente activo cosmetico o farmaceutico, y un solvente volatil; y su uso para tratar psoriasis, micosis entre otras enfermedades.
ES2478264T3 (es) Glicerosomas y uso de estos en preparaciones farmacéuticas y cosméticas para aplicación tópica
UY31017A1 (es) Uso de un inhibidor del factor &(alfa) de necrosis tumoral mas un antihistaminico para el tratamiento de la rinitis alérgica y la conjuntivitis alérgica.
WO2009063378A3 (en) Olive oil formulation for pain relief
CL2008003057A1 (es) Combinacion farmaceutica que comprende un derivado de purina y un corticoide, agonista de beta-2 adrenoceptor, agente antimuscarinico, entre otros; composicion farmaceutica; y su uso para tratar enfermedades inflamatorias u obstructivas de las vias respiratorias.
UY32187A (es) Composiciones farmaceuticas topicas
SV2010003559A (es) Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrofilos
ECSP11010762A (es) Composición tópica para el tratamiento de queratosis actínica
CL2008001323A1 (es) Compuestos derivados de triazolil aminopiridina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
CL2012001019A1 (es) Composicion farmaceutica que comprende una proenzima de proteasa seleccionada de al menos tripsinogeno y quimiotripsinogeno y un agente activo seleccionado de al menos un compuesto de selenio, un compuesto vanilloide, un agente reductor de glicolisis citoplasmica y opcionalmente una glucosidohidrolasa; y uso para tratar cancer.
CL2011003327A1 (es) Composicion farmaceutica que comprende finafloxacina y un agente antiinflamatorio; uso en el tratamiento de infecciones oftalmicas, oticas o nasales.
AR068669A1 (es) Metodo para aliviar la queratoconjuntivitis seca
UY31273A1 (es) Fenilendiaminas sustituidas como inhibidores de la interaccion entre mdm2 y p53
UY31788A (es) Formulación farmacéutica sólida con liberación retardada

Legal Events

Date Code Title Description
FA Abandonment or withdrawal